EUVIMEDEUVIMED entdecken
Crossref

Visceral Organ Malignancy in Patients Undergoing Primary Total Hip Arthroplasty: Is There a Role for Aspirin Prophylaxis?

Saad Tarabichi, Jens T Verhey, Joseph C Brinkman, Rigel P Hall, Ryan Lebens, David G Deckey, Mark J Spangehl, Joshua S Bingham

The Journal of Arthroplasty · 2025

DOI: 10.1016/j.arth.2025.05.105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2025. Verfasst von Saad Tarabichi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Mayo Clinic Arizona, Phoenix, Arizona. Hauptthemen laut MEDLINE: Aspirin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although aspirin has become the prophylactic agent of choice for venous thromboembolism prevention in low-risk patients undergoing primary total hip arthroplasty (THA), there remains a paucity of data in the literature on the efficacy of aspirin as a mode of chemoprophylaxis in patients who had recent cancer. The purpose of this study was to determine the efficacy of aspirin versus other anticoagulant medications in primary THA patients who were diagnosed with a visceral organ malignancy within 1 year before their arthroplasty procedure. METHODS: This study used a national database to identify patients who underwent primary THA between 2012 and 2022. Only patients who had a diagnosis code for a visceral organ malignancy within 1 year before their primary THA were included. Using demographic data, medical comorbidities, and preoperative anticoagulation use, primary THA patients who had cancer who were prescribed aspirin for thromboprophylaxis (n = 2,342) were propensity score matched on a 1:1 basis to those who were on non-aspirin medications (n = 2,342). The odds of developing 90-day medical and surgical complications were assessed and compared between patients prescribed aspirin only versus other types of chemoprophylaxis. There were 4,684 matched patients undergoing primary THA included in the analysis. RESULTS: Patients in the aspirin-group had significantly lower odds of developing deep vein thrombosis (1.2 versus 2.0%; odds ratio [OR] 0.58 [0.4 to 0.9]; P = 0.027) and pulmonary embolism (0.5 versus 1.1%; OR 0.44 [0.2 to 0.9]; P = 0.023), when compared to their counterparts in the non-aspirin group. Furthermore, patients prescribed aspirin were significantly less likely to develop periprosthetic joint infection (0.8 versus 1.8%; OR 0.42 [0.2 to 0.7]; P = 0.003). CONCLUSIONS: Based on these findings, it appears that aspirin is a safe and effective method of venous thromboembolism prophylaxis in patients with an active visceral organ cancer that are undergoing primary THA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinArthroplasty, Replacement, HipVenous ThromboembolismNeoplasmsHumansFemaleMaleAgedMiddle AgedRetrospective StudiesAnticoagulantsPostoperative ComplicationsVenous ThrombosisDatabases, Factual

Stichwörter der Autor:innen

aspirindeep vein thrombosispulmonary embolismtotal hip arthroplastyvisceral organ malignancy

Substanzen

AspirinAnticoagulants

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Mayo Clinic Arizona, Phoenix, Arizona.
  • Creighton University School of Medicine, Phoenix, Arizona.
  • Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
  • Department of Orthopaedic Surgery, Duke University Hospital, Durham, North Carolina.

Zitieren

APA

Tarabichi, S., Verhey, J. T., Brinkman, J. C., Hall, R. P., Lebens, R., Deckey, D. G., Spangehl, M. J., & Bingham, J. S. (2025). Visceral Organ Malignancy in Patients Undergoing Primary Total Hip Arthroplasty: Is There a Role for Aspirin Prophylaxis?. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2025.05.105

Vancouver

Tarabichi S, Verhey JT, Brinkman JC, Hall RP, Lebens R, Deckey DG, et al. Visceral Organ Malignancy in Patients Undergoing Primary Total Hip Arthroplasty: Is There a Role for Aspirin Prophylaxis?. The Journal of Arthroplasty. 2025. doi:10.1016/j.arth.2025.05.105

BibTeX
@article{Tarabichi2025,
  author = {Tarabichi, Saad and Verhey, Jens T and Brinkman, Joseph C and Hall, Rigel P and Lebens, Ryan and Deckey, David G and Spangehl, Mark J and Bingham, Joshua S},
  title = {Visceral Organ Malignancy in Patients Undergoing Primary Total Hip Arthroplasty: Is There a Role for Aspirin Prophylaxis?},
  journal = {The Journal of Arthroplasty},
  year = {2025},
  doi = {10.1016/j.arth.2025.05.105}
}
Kostenlos starten →